Since Cellectis S.A. (NASDAQ:CLLS) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	25.47M	32.45	82.53M	-2.11	0.00
Protagonist Therapeutics Inc.	39.85M	5.09	28.11M	-1.30	0.00

Table 1 highlights Cellectis S.A. and Protagonist Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Cellectis S.A. and Protagonist Therapeutics Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-324.03%	-23%	-18.8%
Protagonist Therapeutics Inc.	-70.54%	-24.1%	-18.8%

Liquidity

Cellectis S.A.’s Current Ratio and Quick Ratio are 11.2 and 11.2 respectively. The Current Ratio and Quick Ratio of its competitor Protagonist Therapeutics Inc. are 6.1 and 6.1 respectively. Cellectis S.A. therefore has a better chance of paying off short and long-term obligations compared to Protagonist Therapeutics Inc.

Analyst Ratings

In next table is delivered Cellectis S.A. and Protagonist Therapeutics Inc.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	1	0	2.00
Protagonist Therapeutics Inc.	0	0	1	3.00

Cellectis S.A.’s average price target is $25, while its potential upside is 27.94%. Competitively Protagonist Therapeutics Inc. has a consensus price target of $17, with potential upside of 102.62%. The data from earlier shows that analysts opinion suggest that Protagonist Therapeutics Inc. seems more appealing than Cellectis S.A.

Institutional & Insider Ownership

Institutional investors held 29.4% of Cellectis S.A. shares and 0% of Protagonist Therapeutics Inc. shares. Insiders Comparatively, held 1.8% of Protagonist Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	-12.03%	-27.86%	-25.47%	-35.88%	-21.71%	-33.55%
Protagonist Therapeutics Inc.	7.57%	-23.09%	-20.18%	-3.47%	-63.94%	-66.54%

For the past year Cellectis S.A.’s stock price has smaller decline than Protagonist Therapeutics Inc.

Summary

Protagonist Therapeutics Inc. beats on 7 of the 11 factors Cellectis S.A.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs. It primarily focuses on developing oral peptide drugs. The companyÂ’s lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease (IBD); and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD. It is also developing PTG-300, an injectable hepcidin mimetic peptide that is in pre-clinical development stage to treat iron overload disorders, such as b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.